Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBITDA (2016 - 2025)

Historic EBITDA for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.3 million.

  • Enanta Pharmaceuticals' EBITDA rose 5220.24% to -$11.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$73.1 million, marking a year-over-year increase of 3379.22%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its EBITDA stood at -$11.3 million for Q4 2025, which was up 5220.24% from -$18.4 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBITDA peaked at -$11.3 million during Q4 2025, and registered a low of -$39.5 million during Q1 2023.
  • Moreover, its 5-year median value for EBITDA was -$30.2 million (2021), whereas its average is -$28.8 million.
  • In the last 5 years, Enanta Pharmaceuticals' EBITDA plummeted by 15010.53% in 2021 and then soared by 5220.24% in 2025.
  • Enanta Pharmaceuticals' EBITDA (Quarter) stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then dropped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
  • Its EBITDA stands at -$11.3 million for Q4 2025, versus -$18.4 million for Q3 2025 and -$18.9 million for Q2 2025.